Insmed Inc (INSM)vsKymera Therapeutics Inc (KYMR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
KYMR
Kymera Therapeutics Inc
$78.93
+6.06%
HEALTHCARE · Cap: $6.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1447% more annual revenue ($606.42M vs $39.21M). KYMR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
KYMR
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Grey zone — moderate risk
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : KYMR
The strongest argument for KYMR centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Altman Z-Score, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while KYMR is a value play — different risk/reward profiles.
KYMR carries more volatility with a beta of 2.30 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
KYMR generates stronger free cash flow (-67M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?